Business
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical
About this update from Ardelyx, Inc.
[{"type":"image","alt":"Ardelyx, Inc.","displaySize":"","headline":null,"caption":"Ardelyx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":69,"url":"https://media.zenfs.com/en/globenewswire.com/0b16c7d3f50416d895ec92e34e19858e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MgPvxPnNoevfPj4GVpeYhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0b16c7d3f50416d895ec92e34e19858e","width":300,"height":69}},"lazy":false},{"type":"text","content":"IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million","length":92,"tagName":"p"},{"type":"text","content":"Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses","length":83,"tagName":"p"},{"type":"text","content":"Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched","length":91,"tagName":"p"},{"type":"text","content":"Company is well capitalized to meet current business objectives","length":63,"tagName":"p"},{"type":"text","content":"Conference call scheduled for 4:30 PM Eastern Time","length":50,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.","length":372,"tagName":"p"},{"type":"text","content":"“The results we delivered in 2025 reflect our team’s hard work and disciplined execution to bring our medicines to more patients in need, underscored by significant IBSRELA growth, increased adoption of XPHOZAH and rapid advancement of our clinical development programs,” said Mike Raab, president and chief executive officer of Ardelyx. “As we look to build on this strong momentum, we see 2026 as a pivotal opportunity to further evolve our business into a meaningful enterprise built on a broad, thoughtful portfolio of best-in-class medicines. Our long-term strategy remains clear and unwavering: to deliver novel therapies to patients with significant unmet medical needs and generate sustained value for shareholders.”","length":724,"tagName":"p"},{"type":"text","co...